Prurigo nodularis
☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
References
Prurigo nodularis ganda rinogara kwenguva refu rinoratidzwa nemapundu akawanda akasimba uye ma nodules, anowanzo kuwanikwa pamativi ekunze emaoko nemakumbo. Aya mapundu anogona kusiyana-siyana muruvara kubva kunyama-toned kusvika kupingi uye anokwenya zvakanyanya. Zvinogona kukanganisa vanhu vezera ripi zvaro uye zvinowanzobatanidzwa nemamwe mamiriro eganda anokonzera kusingaperi kuputika, seatopic dermatitis. Mishonga yekurapa inosanganisira yakasimba anti-itch mishonga, zvinodhaka zvinokanganisa immune system, uye mishonga inonangana netsinga system. Kutarisira prurigo nodularis kazhinji kunosanganisira kurapwa kwenguva refu.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Kurapa kunowanzobatanidza kushandisa makirimu kana majekiseni esteroid panzvimbo yakakanganiswa. Muzviitiko zvakanyanya kuoma kana kusindimara, marapirwo akaita serenje rekurapa kana mishonga inodzvanyirira immune system inogona kudiwa. Thalidomide uye lenalidomide isarudzo dzezviitiko zvakakomba, asi dzinogona kuve nemhedzisiro yakaipa. Mishonga mitsva (opioid receptor antagonists, neurokinin-1 receptor antagonists) inoratidza chivimbiso mukurapa prurigo nodularis ine mhedzisiro shoma kana ichienzaniswa nethalidomide kana lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo ichimiro cheganda chinoratidzwa nekukwenya kwenguva refu (kunogara kwemavhiki matanhatu) , maronda ane chekuita neganda, uye nhoroondo yekukwenya kazhinji. Inosanganisira neuroinflammation uye fibrosis muganda.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis idambudziko reganda rinogara kwenguva refu rinoratidzwa nemapundu anovava. Hatinyatso ziva kuti chii chinozvikonzeresa, asi zvinoita sekunge nyaya dzedziviriro nedzetsinga dzinoita basa mukukwenya-kukwenya kutenderera. Parizvino, hapana marapiro akatenderwa neUS FDA akananga prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Kurapa ― OTC Zvinodhaka
Kugeza nzvimbo yakakuvara nesipo haibatsiri zvachose uye inogona kuipa. Mafuta eOTC steroid anogona kubatsira kubvisa zviratidzo, asi anowanzoda kushandiswa kwemavhiki akawanda kuti avandudze. Kuramba uchitora antihistamines kunobatsirawo kudzikisira kukoira.
#OTC steroid ointment
#OTC antihistamine
○ Kurapwa
#Intralesional triamcinolone injection